Study backs rapid test for "super bugs":
This article was originally published in Clinica
Canadian firm ID Biomedical will file in February for FDA-clearance to market its rapid test for methicillin-resistant Staphylococcus aureus (MRSA) after receiving promising preliminary results in US clinical trials. The test for the potentially fatal so-called "superbugs", which are becoming increasingly prevalent in hospitals, was shown to have an accuracy of 100% in an analysis of 308 samples. The Velogene Rapid MRSA test, which is based on the Vancouver, British Columbia company's Cycling Probe Technology, detects the mecA gene responsible for antibiotic resistance.
You may also be interested in...
Our updated graphic tracker of key developments from the leading vaccine candidates.
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.